Aussie Pharma Pharmaxis Submits Bronchitol Application to China’s State FDA
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sydney-based Pharmaxis submitted a clinical trial application to China's State FDA for chronic lung condition drug Bronchitol (mannitol) for treatment of bronchiectasis, the company announced March 7
You may also be interested in...
Sydney-Based Pharmaxis Gets FDA Green Light On Bronchitol SPA
PERTH, Australia - Sydney-based Pharmaxis and the U.S. FDA reached an agreement on a Phase III registration trial of Bronchitol (mannitol) for treatment of bronchiectasis through the special protocol assessment process, which will form the basis of the company's efficacy claim, PharmAxis announced June 20
Sydney-Based Pharmaxis Gets FDA Green Light On Bronchitol SPA
PERTH, Australia - Sydney-based Pharmaxis and the U.S. FDA reached an agreement on a Phase III registration trial of Bronchitol (mannitol) for treatment of bronchiectasis through the special protocol assessment process, which will form the basis of the company's efficacy claim, PharmAxis announced June 20
Australia, New Zealand Roundup: Pharmaxis, CSL, PHARMAC
Pharmaxis Completes Long-Term Safety Study Of Bronchitol